Important Details : BSVL Nod Trail Ulinastatin for COVID-19

June 14, 2020

In the serious scenario like the pandemic of COVID-19, when everyone is expecting for the vaccine to come a great has emerged.
Bharat Serums and Vaccines Ltd has gotten gesture from Drug Controller General of India to lead stage III clinical examination on Ulinastatin for gentle to direct Acute Respiratory Distress Syndrome (ARDS) patients with COVID-19.
The clinical trials are expected to start in hospitals very soon. The Mortality Rate is at its peak when an individual suffering with COVID-19 infection develops ARDS (Acute Respiratory Distress Syndrome) and pneumonia. ARDS causes dry hack, substantial breathing, breathing challenges and expanded pulse.
In this case, Ulinastatin can be considered as a remedy to combat the underlying inflammatory condition related to ARDS in COVID-19 patients.
Sanjiv Navangul, MD and CEO, BSVL said that they have found effective antiviral agents and therapies to combat underlying pathology of COVID-19.
The organization will join the world class club of driving pharma firms, for example, Sun Pharmaceutical Industries, Glenmark Pharmaceuticals, and Strides Pharma Science that have just begun clinical preliminaries for expected medications for COVID-19.
The trials will be conducted in 6 to 8 hospitals only.

Bharat Serums and Vaccines Limited is a pharmaceutical company and specializes in biological and biotechnological products such as hormones, antifungals, plasma derivatives and serum preparations.
Bharat Serums and Vaccines Limited is famous for its innovation and high ended technology in the field of pharmaceutical research.